Novartis (NVS) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2238956/novartis-nvs-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2238956
Mar 11, 2024 - Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.
0
Novartis (NVS) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2239592/novartis-nvs-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2239592
Mar 12, 2024 - In the most recent trading session, Novartis (NVS) closed at $99.77, indicating a -1.58% shift from the previous trading day.
0
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089
Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
0
Novartis (NVS) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2242497/novartis-nvs-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2242497
Mar 18, 2024 - In the latest trading session, Novartis (NVS) closed at $95.92, marking a -1.39% move from the previous day.
0
Novartis (NVS) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2249443/novartis-nvs-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2249443
Apr 02, 2024 - In the most recent trading session, Novartis (NVS) closed at $94.41, indicating a -1.52% shift from the previous trading day.
0
Top Analyst Reports for Novartis, American Express & ConocoPhillips
https://www.zacks.com/commentary/2259373/top-analyst-reports-for-novartis-american-express-conocophillips?cid=CS-ZC-FT-research_daily-2259373
Apr 22, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).
0
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2265278/incyte-s-incy-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2265278
Apr 30, 2024 - Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
0
What Makes Wolters Kluwer NV (WTKWY) a Good Fit for 'Trend Investing'
https://www.zacks.com/stock/news/2194044/what-makes-wolters-kluwer-nv-wtkwy-a-good-fit-for-trend-investing?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2194044
Dec 06, 2023 - Wolters Kluwer NV (WTKWY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
0
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063
Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
0
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
https://www.zacks.com/stock/news/2200609/roche-s-rhhby-sbla-for-xolair-gets-fda-priority-review-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200609
Dec 20, 2023 - The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.
0